FDA-approved GLP-1 receptor agonists include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin), exenatide (Bydureon BCise), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
Similar content being viewed by others Introduction Obesity is a complex, multifactorial chronic disease characterized by excess adiposity, with or without abnormal distribution or function of adipose tissue, leading to adverse effects on health
Furthermore, when comparing the cytotoxicity of FA-SNCD@SBA-15/ENZ with free ENZ in the presence of GSH on PC3 cell lines, it was observed that FA-SNCD@SBA-15/ENZ displayed significantly higher cytotoxicity
What you should do if you are taking a GLP-1 medication If you are currently on a GLP-1 receptor agonist for diabetes (or weight), the main takeaway is not stop. The practical takeaway is: Do not discontinue suddenly without talking to your clinician
Pharmaceutical companies have also invested heavily in direct-to-patient marketing, with television commercials and online ads promoting the benefits of their brand names for weight loss and diabetes
The diverse metabolic roles of peripheral serotonin
